ALMS plunges 57% after lupus Phase 2b topline misses goals
Alumis Inc. shares fell 57% Tuesday, its worst day since the mid-2024 IPO, after topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus missed the study’s main goals.
Shares of Alumis Inc. (ALMS) fell 57% on Tuesday, marking their worst day since the company’s mid-2024 IPO, after the biotech said its mid-stage lupus study failed to meet its main goals. The move came after topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus.